Medicare Part D Coverage Gap Discount Proposal Challenged In Study
Executive Summary
Analysis sponsored by a biopharma-backed group challenges MedPAC proposal for changing Part D procedures in a way that could reduce beneficiary incentives to choose high-cost branded drugs while in the coverage gap.
You may also be interested in...
Part D Reform Proposals From MedPAC May Find Traction After Election
Advisory group’s cost control recommendations on reinsurance, partial fills, and preferred specialty tiers could end up on the legislative agenda, particularly if Hillary Clinton is president.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.